Alnylam Pharmaceuticals Inc.

ALNY | NASDAQ

Price Alert Chart Builder DCF Calculator

$244.32

+$4.76 (+1.99%)

At close: Sep 21, 2026, 4:00 PM ET

$244.35

+$0.03 (+0.01%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Income Statement Balance Sheet Cashflow Statement Ratios

Annual Quarterly TTM

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021	FY 2020 Dec 30, 2020
Revenue	3.71B	2.25B	1.83B	1.04B	844.29M	492.85M
Cost of Revenue	677.17M	323.37M	310.41M	168.82M	140.14M	78.05M
Gross Profit	3.04B	1.92B	1.52B	868.6M	704.14M	414.8M
Operating Income	501.58M	-176.89M	-282.18M	-785.07M	-708.65M	-828.44M
Interest Income	111.47M	121.99M	95.56M	24.81M	1.58M	11.81M
Pretax Income	323.15M	-377.38M	-433.52M	-1.13B	-852.14M	-855.6M
Net Income	313.75M	-278.16M	-440.24M	-1.13B	-852.82M	-858.28M
Selling & General & Admin	1.21B	975.53M	795.65M	770.66M	620.64M	588.42M
Research & Development	1.32B	1.13B	1B	883.02M	792.16M	654.82M
Other Expenses	n/a	n/a	n/a	n/a	-2.05M	n/a
Operating Expenses	2.54B	2.1B	1.8B	1.65B	1.41B	1.24B
Interest Expense	252.63M	141.86M	121.22M	155.97M	143.02M	84.5M
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	3.21B	2.43B	2.11B	1.82B	1.55B	1.32B
Income Tax Expense	9.41M	-99.22M	6.73M	4.16M	680K	2.68M
Shares Outstanding (Basic)	131M	127.65M	124.91M	121.69M	118.45M	114.99M
Shares Outstanding (Diluted)	134.68M	127.65M	124.91M	121.69M	118.45M	114.99M
EPS (Basic)	2.39	-2.18	-3.52	-9.30	-7.20	-7.46
EPS (Diluted)	2.33	-2.18	-3.52	-9.30	-7.20	-7.46
EBITDA	631.44M	-178.85M	-258.24M	-926.56M	-661.56M	-736.33M
EBIT	575.78M	-235.52M	-312.3M	-971.03M	-709.12M	-771.1M
Depreciation & Amortization	55.66M	56.67M	54.05M	44.47M	47.57M	34.77M